JP2015509107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509107A5 JP2015509107A5 JP2014555045A JP2014555045A JP2015509107A5 JP 2015509107 A5 JP2015509107 A5 JP 2015509107A5 JP 2014555045 A JP2014555045 A JP 2014555045A JP 2014555045 A JP2014555045 A JP 2014555045A JP 2015509107 A5 JP2015509107 A5 JP 2015509107A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- ring
- lymphoma
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000005141 Otitis Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 206010039710 Scleroderma Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 208000019258 ear infection Diseases 0.000 claims 4
- 230000003325 follicular Effects 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 206010034674 peritonitis Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008822 Ankylosis Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 206010003011 Appendicitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 206010057254 Connective tissue inflammation Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004145 Endometritis Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 201000011275 Epicondylitis Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010016228 Fasciitis Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000005577 Gastroenteritis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 206010023198 Joint ankylosis Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 201000008197 Laryngitis Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010031252 Osteomyelitis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010034038 Parotitis Diseases 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010035742 Pneumonitis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010036774 Proctitis Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 2
- 208000033464 Reiter syndrome Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 208000002240 Tennis Elbow Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010045240 Type I hypersensitivity Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010046914 Vaginal infection Diseases 0.000 claims 2
- 201000008100 Vaginitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000010217 blepharitis Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 206010008323 cervicitis Diseases 0.000 claims 2
- 208000003167 cholangitis Diseases 0.000 claims 2
- 201000001352 cholecystitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 208000010227 enterocolitis Diseases 0.000 claims 2
- 210000000918 epididymis Anatomy 0.000 claims 2
- 201000010063 epididymitis Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 208000004396 mastitis Diseases 0.000 claims 2
- 210000001370 mediastinum Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 230000002232 neuromuscular Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000005963 oophoritis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000001297 phlebitis Diseases 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001541 thymus gland Anatomy 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 230000009959 type I hypersensitivity Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- 208000002003 vulvitis Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QPWWALBJROMWHE-UHFFFAOYSA-N 1-[2-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]prop-2-en-1-one Chemical compound C1=2C(N)=NC=NC=2N(C2CC3(C2)CCN(CC3)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 QPWWALBJROMWHE-UHFFFAOYSA-N 0.000 claims 1
- MDOOZFHNLMQRHG-UHFFFAOYSA-N 1-[6-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound C1=2C(N)=NC=NC=2N(C2CC3(C2)CN(C3)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 MDOOZFHNLMQRHG-UHFFFAOYSA-N 0.000 claims 1
- ISDIBDPXVWNENH-UHFFFAOYSA-N 1-[7-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-azaspiro[3.5]nonan-2-yl]prop-2-en-1-one Chemical compound C1=2C(N)=NC=NC=2N(C2CCC3(CN(C3)C(=O)C=C)CC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 ISDIBDPXVWNENH-UHFFFAOYSA-N 0.000 claims 1
- -1 2- (4-Amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl) -6-azaspiro [3.5] nonan-6-yl Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000002927 anti-mitotic effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261632781P | 2012-01-31 | 2012-01-31 | |
| US61/632,781 | 2012-01-31 | ||
| PCT/CA2013/000085 WO2013113097A1 (en) | 2012-01-31 | 2013-01-30 | Cyclic molecules as bruton's tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509107A JP2015509107A (ja) | 2015-03-26 |
| JP2015509107A5 true JP2015509107A5 (enExample) | 2015-07-02 |
| JP5985658B2 JP5985658B2 (ja) | 2016-09-06 |
Family
ID=48904331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555045A Expired - Fee Related JP5985658B2 (ja) | 2012-01-31 | 2013-01-30 | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9458162B2 (enExample) |
| EP (1) | EP2809673B1 (enExample) |
| JP (1) | JP5985658B2 (enExample) |
| CN (1) | CN104080789B (enExample) |
| CA (1) | CA2863239C (enExample) |
| WO (1) | WO2013113097A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6348492B2 (ja) | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物 |
| US8895750B2 (en) | 2013-03-14 | 2014-11-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as BTK inhibitors |
| US8940893B2 (en) | 2013-03-15 | 2015-01-27 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as BTK inhibitors |
| JP6486954B2 (ja) * | 2014-01-29 | 2019-03-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのピラゾール化合物 |
| BR112016016844A2 (pt) * | 2014-02-03 | 2017-08-08 | Cadila Healthcare Ltd | Compostos heterocíclicos |
| PL3166608T3 (pl) * | 2014-07-07 | 2019-07-31 | Jiangsu Hengrui Medicine Co., Ltd. | Związki aminopirydazynonowe jako inhibitory kinaz białkowych |
| TWI578574B (zh) * | 2014-07-14 | 2017-04-11 | 新世紀光電股份有限公司 | 發光元件結構 |
| WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2016106652A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
| WO2017031138A1 (en) * | 2015-08-17 | 2017-02-23 | Infinite Arthroscopy Inc, Limited | Light source |
| WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
| CN106588914B (zh) * | 2015-10-16 | 2018-11-02 | 陈剑 | 具有取代吡啶并咪唑类衍生物，其制备及其在医药上的应用 |
| CN108368086B (zh) | 2015-12-16 | 2021-01-08 | 勃林格殷格翰国际有限公司 | 可用于治疗自身免疫疾病的二吡唑基衍生物 |
| EP3402789B1 (en) | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
| US10793566B2 (en) | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102699906B1 (ko) * | 2016-01-21 | 2024-08-29 | 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 | 브루톤 티로신 키나제 억제제 |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| JP6972002B2 (ja) | 2016-03-11 | 2021-11-24 | エンジェル・ファーマシューティカル・カンパニー・リミテッド | ブルトン型チロシンキナーゼを調節する化合物及び方法 |
| AU2017241524B2 (en) | 2016-03-28 | 2021-07-08 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| CA2939286A1 (en) * | 2016-08-17 | 2018-02-17 | Pharmascience Inc. | Spirocyclic containing compounds and pharmaceutical uses thereof |
| US11186578B2 (en) | 2016-08-17 | 2021-11-30 | Shenzhen Targetrx, Inc. | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| CN106831787B (zh) * | 2017-01-20 | 2018-10-23 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
| AU2018237123B2 (en) | 2017-03-22 | 2022-08-04 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
| JP7166331B2 (ja) | 2017-08-01 | 2022-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 中間体化合物及び方法 |
| WO2020015735A1 (zh) * | 2018-07-20 | 2020-01-23 | 正大天晴药业集团股份有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药（上海）有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| WO2022253250A1 (zh) * | 2021-06-01 | 2022-12-08 | 正大天晴药业集团股份有限公司 | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 |
| WO2025240240A1 (en) * | 2024-05-14 | 2025-11-20 | Dana-Farber Cancer Institute, Inc. | Novel spirocycle derivatives as inhibitors of hck |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK3842001A3 (en) | 1998-09-18 | 2002-04-04 | Basf Ag | Pyrrolopyrimidines as protein kinase inhibitors (revised) |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| CN101883774A (zh) * | 2007-10-16 | 2010-11-10 | 惠氏有限责任公司 | 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途 |
| CN105362277A (zh) * | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| EP2324036B1 (en) | 2008-07-16 | 2014-12-03 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2011029915A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
| US20120289501A1 (en) * | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| SG195100A1 (en) * | 2011-07-01 | 2013-12-30 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
-
2013
- 2013-01-30 CN CN201380007581.5A patent/CN104080789B/zh active Active
- 2013-01-30 US US14/375,539 patent/US9458162B2/en not_active Expired - Fee Related
- 2013-01-30 EP EP13743950.1A patent/EP2809673B1/en not_active Not-in-force
- 2013-01-30 JP JP2014555045A patent/JP5985658B2/ja not_active Expired - Fee Related
- 2013-01-30 WO PCT/CA2013/000085 patent/WO2013113097A1/en not_active Ceased
- 2013-01-30 CA CA2863239A patent/CA2863239C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509107A5 (enExample) | ||
| NZ707432A (en) | Pyrazolopyrimidine compounds | |
| HRP20191126T2 (hr) | Spojevi pirazolopirimidina ako inhibitori kinaze | |
| JP2016531870A5 (enExample) | ||
| TWI824309B (zh) | 作為PI3K-γ抑制劑之雜環化合物 | |
| KR101763656B1 (ko) | Ｐｉ3ｋ 저해물질로서의 피리미디논 | |
| CA2823969C (en) | 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine derivatives as fak/pyk2 inhibitors | |
| ES2814289T3 (es) | 1,5-Dihidro-4H-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4H-pirazolo[4,3-c]piridin-4-onas como inhibidores de la PDE1 | |
| CA2836410A1 (en) | Tyrosine kinase inhibitors | |
| JP2015528801A5 (enExample) | ||
| JP2022534261A (ja) | Ｄｎａ依存性タンパク質キナーゼ阻害剤 | |
| HRP20201835T1 (hr) | Spojevi korisni kao inhibitori kinaze | |
| JP2015503618A5 (enExample) | ||
| AU2021373162B2 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| CA2841080A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2018522852A5 (enExample) | ||
| NZ702041A (en) | Heterocyclic containing entities, compositions and methods | |
| US20220040184A1 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
| KR20150023799A (ko) | 치환 모르폴린을 포함한 신규 2,3-디하이드로-1H-이미다조[1,2-a]피리미딘-5-온 및 1,2,3,4-테트라하이드로피리미도[1,2-a]피리미딘-6-온 유도체, 그의 제조 방법 및 약학적 용도 | |
| AU2020386189B2 (en) | Adenosine receptor antagonist compounds | |
| RU2019103446A (ru) | Спироциклические соединения и их фармацевтические применения | |
| BR112021005936A2 (pt) | moduladores de monoacilglicerol lipase | |
| WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |